CollPlant Biotechnologies Ltd., a leader in regenerative and aesthetics medicine, has announced the expansion of its European distribution network for its Vergenix™ STR product through a new agreement in Poland. Vergenix™ STR, which utilizes CollPlant's rhCollagen technology, is designed to treat tendinopathy by promoting tendon healing and repair. The product works by forming a gel matrix that allows for the sustained release of growth factors at the site of injury, enhancing the healing process. The company plans to deliver the first shipment to the Polish distributor by the end of the year and is focused on further expanding its global distribution network for Vergenix™ STR in additional markets.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collplant Biotechnologies Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO73217) on September 15, 2025, and is solely responsible for the information contained therein.